COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Adam Meijer, Héloïse Lucaccioni et al.|Influenza and Other Respiratory Viruses|2025Cited by 10
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24Esther Kissling, Marine Maurel, Francisco Pozo et al.|Eurosurveillance|2025Cited by 9
COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Esther Kissling, Nuno Verdasca et al.|SSRN Electronic Journal|2025Cited by 0
Recommendations for estimating and reporting vaccine effectiveness by time since vaccination: a COVID-19 case studyEsther Kissling, on behalf of I-MOVE-COVID- and ECDC primary care study teams, Mariëtte Hooiveld et al.|American Journal of Epidemiology|2025Cited by 0